A breast-implant concern can involve rupture, capsular contracture, infection, pain, a fluid collection, a mass, labeling or warning questions, device performance, or another medical condition. The symptom or diagnosis does not identify the responsible party or legal theory. Begin with the exact device, the medical record, and the product history.

Product identification, medical diagnosis, manufacturer conduct, provider conduct, and causation must be proved separately.

Identify each implant before evaluating a product theory

  • Manufacturer, product name, model, style, size, fill, surface texture, serial and lot numbers, and unique device identifier when available
  • Implant and tissue-expander dates, side, facility, surgeon, operative report, stickers, device card, inventory and distribution records
  • Patient booklet, boxed warning, decision checklist, consent, labeling, instructions, advertisements, and warnings supplied at the relevant time
  • Revision, removal, replacement, imaging, pathology, culture, cytology, oncology, and complication records
  • Recall or safety communications tied to the exact product rather than to breast implants as a single undifferentiated category

Use current FDA information for medical-device risks

The FDA’s breast-implant risk and complication page discusses rupture and other local complications as well as reported malignancies in tissue around implants. The article’s former 2018 report counts are no longer an appropriate current reference.

The FDA’s BIA-ALCL questions and answers explains that breast implant-associated anaplastic large cell lymphoma is a lymphoma of the immune system, not breast cancer. The FDA identifies persistent swelling, a mass, or pain near an implant as symptoms that warrant medical evaluation and reports a higher risk with textured-surface implants than with smooth-surface implants.

A legal page cannot diagnose BIA-ALCL or advise whether an implant should be removed. Medical professionals should evaluate symptoms, testing, treatment, and individual risk. Preserve the diagnostic specimens, imaging, pathology, operative findings, and product identity without delaying care.

North Carolina product claims follow Chapter 99B

Chapter 99B of the North Carolina General Statutes defines product-liability actions and addresses warnings, design, sellers, alteration, use, causation, and defenses. G.S. 99B-1.1 states that North Carolina does not use strict liability in tort for product-liability actions.

A warning theory under G.S. 99B-5 requires more than showing that a risk existed. The evidence must address the warning or instruction, unreasonable conduct, manufacturer or seller knowledge under the statute, substantial risk, and proximate causation. A design theory under G.S. 99B-6 has its own unreasonable-design, causation, alternative-design, utility, and feasibility questions.

Separate product conduct from medical care

A manufacturer or seller may be evaluated for design, manufacture, testing, warnings, instructions, labeling, marketing, or distribution. A surgeon, facility, radiologist, pathologist, or another healthcare provider presents different questions about informed consent, procedure, follow-up, diagnosis, treatment, and the medical-malpractice framework. The same medical event can require separate legal and expert analyses.

Preserve an explanted device without altering it

  • Ask that each implant, capsule, component, packaging item, specimen, photograph, and pathology material be identified and preserved under a documented custody process.
  • Record who removed, received, stored, transferred, photographed, tested, cleaned, cut, or disposed of each item and when.
  • Do not authorize destructive testing, return to a manufacturer, or disposal without understanding the medical need, protocol, notice, and preservation consequences.
  • Keep the pre-removal and post-removal condition distinct from later handling, shipping damage, laboratory preparation, or alteration.
  • Build a dated chronology of symptoms, disclosure, diagnosis, device communications, revision decisions, treatment, expenses, work effects, and daily-function changes.

The related guide explaining North Carolina’s product-liability framework and rejection of strict liability provides the broader design, warning, seller, alteration, use, and deadline context. This page remains focused on breast-implant identification and coordinated product and medical evidence.

Rosensteel Fleishman Car Accident & Injury Lawyers provides information about consulting a North Carolina personal-injury lawyer when a breast-implant concern may involve product-related harm. Device identity, legal theory, qualified evidence, causation, defenses, deadlines, and damages depend on the particular product and medical record.

Sources